Connection
Risha Gidwani to Cost-Benefit Analysis
This is a "connection" page, showing publications Risha Gidwani has written about Cost-Benefit Analysis.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.386 |
|
|
|
-
Gidwani R, Russell LB. Estimating Transition Probabilities from Published Evidence: A Tutorial for Decision Modelers. Pharmacoeconomics. 2020 11; 38(11):1153-1164.
Score: 0.148
-
Gidwani-Marszowski R, Owens DK, Lo J, Goldhaber-Fiebert JD, Asch SM, Barnett PG. The Costs of Hepatitis C by Liver Disease Stage: Estimates from the Veterans Health Administration. Appl Health Econ Health Policy. 2019 08; 17(4):513-521.
Score: 0.136
-
Gidwani R, Khan ZM, Fenaux P, Beach CL, Pashos CL. A cost-effectiveness analysis of using azacitidine vs. decitabine in treating patients with myelodysplastic syndromes. J Med Econ. 2012; 15(1):145-54.
Score: 0.080
-
Ganz ML, Shah D, Gidwani R, Filonenko A, Su W, Pocoski J, Law A. The cost-effectiveness of the levonorgestrel-releasing intrauterine system for the treatment of idiopathic heavy menstrual bleeding in the United States. Value Health. 2013 Mar-Apr; 16(2):325-33.
Score: 0.022